Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI

被引:57
|
作者
Hoetker, Andreas M. [1 ,2 ]
Mazaheri, Yousef [3 ]
Aras, Oemer [1 ]
Zheng, Junting [4 ]
Moskowitz, Chaya S. [4 ]
Gondo, Tatsuo [5 ]
Matsumoto, Kazuhiro [6 ]
Hricak, Hedvig [1 ]
Akin, Oguz [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10065 USA
[2] Univ Med Mainz, Dept Diagnost & Intervent Radiol, Mainz, Germany
[3] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10065 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
关键词
DWI; MRI; prostate cancer; APPARENT DIFFUSION-COEFFICIENT; ACTIVE SURVEILLANCE; GLEASON SCORE; TUMOR VOLUME; GRADE; PARAMETERS; ADC;
D O I
10.2214/AJR.15.14912
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The objective of this study was to investigate whether the apparent diffusion coefficient (ADC) value from DWI and the forward volume transfer constant (K-trans) value from dynamic contrast-enhanced MRI independently predict prostate cancer aggressiveness, and to determine whether the combination of both parameters performs better than either parameter alone in assessing tumor aggressiveness before treatment. MATERIALS AND METHODS. This retrospective study included 158 men with histopathologically confirmed prostate cancer who underwent 3-T MRI before undergoing prostatectomy in 2011. Whole-mount step-section pathologic maps identified 195 prostate cancer foci that were 0.5 mL or larger; these foci were then volumetrically assessed to calculate the per-tumor ADC and K-trans values. Associations between MRI and histopathologic parameters were assessed using Spearman correlation coefficients, univariate and multivariable logistic regression, and AUCs. RESULTS. The median ADC and K-trans values showed moderate correlation only for tumors for which the Gleason score (GS) was 4 + 4 or higher (rho = 0.547; p = 0.042). The tumor ADC value was statistically significantly associated with all dichotomized GSs (p < 0.005), including a GS of 3 + 3 versus a GS of 3 + 4 or higher (AUC, 0.693; p = 0.001). The tumor K-trans value differed statistically significantly only between tumors with a GS of 3 + 3 and those with a primary Gleason grade of 4 (p <= 0.015), and it made a statistically significant contribution only in differentiating tumors with a GS of 4 + 3 or higher (AUC, 0.711; p < 0.001) and those with a GS of 4 + 4 or higher (AUC, 0.788; p < 0.001) from lower-grade tumors. Combining ADC and K-trans values improved diagnostic performance in characterizing tumors with a GS of 4 + 3 or higher and those with a GS of 4 + 4 or higher (AUC, 0.739 and 0.856, respectively; p < 0.01). CONCLUSION. Although the ADC value helped to differentiate between all GSs, the K-trans value was only a benefit in characterizing more aggressive tumors. Combining these parameters improves their performance in identifying patients with aggressive tumors who may require radical treatment.
引用
收藏
页码:756 / 763
页数:8
相关论文
共 50 条
  • [21] Quantitative dynamic contrast-enhanced MRI of the lung in asthma
    Zhang, Wei-juan
    Niven, Robert
    Young, Simon
    Liu, Yu-zhen
    Parker, Geoffrey
    Naish, Josephine
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [22] Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings
    Lemaitre, Laurent
    Puech, Philippe
    Poncelet, Edouard
    Bouye, Sebastien
    Leroy, Xavier
    Biserte, Jacques
    Villers, Arnauld
    EUROPEAN RADIOLOGY, 2009, 19 (02) : 470 - 480
  • [23] Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings
    Laurent Lemaitre
    Philippe Puech
    Edouard Poncelet
    Sébastien Bouyé
    Xavier Leroy
    Jacques Biserte
    Arnauld Villers
    European Radiology, 2009, 19 : 470 - 480
  • [24] Dynamic Contrast-Enhanced MRI for the Detection of Prostate Cancer: Meta-Analysis
    Tan, Cher Heng
    Hobbs, Brian Paul
    Wei, Wei
    Kundra, Vikas
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2015, 204 (04) : W439 - W448
  • [25] Comparison of Dynamic Contrast-Enhanced MRI and Dynamic Contrast-Enhanced CT Biomarkers in Bladder Cancer
    Naish, J. H.
    McGrath, D. M.
    Bains, L. J.
    Passera, K.
    Roberts, C.
    Watson, Y.
    Cheung, S.
    Taylor, M. B.
    Logue, J. P.
    Buckley, D. L.
    Tessier, J.
    Young, H.
    Waterton, J. C.
    Parker, G. J. M.
    MAGNETIC RESONANCE IN MEDICINE, 2011, 66 (01) : 219 - 226
  • [26] Meta-Analysis of Quantitative Dynamic Contrast-Enhanced MRI for the Assessment of Neoadjuvant Chemotherapy in Breast Cancer
    Wei Ju
    Wang Cong
    Xie Xianxi
    Jiang Daqin
    AMERICAN SURGEON, 2019, 85 (06) : 645 - 653
  • [27] Assessment of ameloblastomas using MRI and dynamic contrast-enhanced MRI
    Asaumi, J
    Hisatomi, M
    Yanagi, Y
    Matsuzaki, H
    Choi, YS
    Kawai, N
    Konouchi, H
    Kishi, K
    EUROPEAN JOURNAL OF RADIOLOGY, 2005, 56 (01) : 25 - 30
  • [28] Correlation of quantitative diffusion-weighted and dynamic contrast-enhanced MRI parameters with prognostic factors in prostate cancer
    Chung, Melody P.
    Margolis, Dan
    Mesko, Shane
    Wang, Jason
    Kupelian, Patrick
    Kamrava, Mitchell
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2014, 58 (05) : 588 - 594
  • [29] Prostate cancer detection using quantitative dynamic contrast-enhanced MR imaging
    Engelbrecht, MR
    Huisman, HJ
    Laheij, RJ
    Jager, GJ
    Van Leenders, A
    Barentsz, JO
    RADIOLOGY, 2001, 221 : 584 - 584
  • [30] Impact of contrast agent injection duration on dynamic contrast-enhanced MRI quantification in prostate cancer
    Klawer, Edzo M. E.
    van Houdt, Petra J.
    Pos, Floris J.
    Heijmink, Stijn W. T. P. J.
    van Osch, Matthias J. P.
    van der Heide, Uulke A.
    NMR IN BIOMEDICINE, 2018, 31 (09)